Thymosin Alpha-1 plus PD-1 therapy in older adults with advanced melanoma

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a phase 2, open-label, single-arm study enrolling patients 60 years or older with unresectable or metastatic melanoma. Participants receive Thymosin Alpha-1 injections plus a PD-1 monoclonal antibody, with safety and tolerance as a key focus alongside preliminary effectiveness measures. Eligibility requires measurable disease, ECOG 0–2, and adequate organ function, with exclusions for recent PD-1/PD-L1/CTLA-4 therapy or recent thymosin exposure. The primary goal is to see how well the combination works, while monitoring adverse events and overall tolerability.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Aged 60 years or older;
2. Diagnosis of malignant melanoma confirmed by pathological histology or cytology examination.
3. According to the 8th edition of AJCC staging, patients with unresectable stage III or IV melanoma;
4. One or more lesions evaluable by RECIST1.1 standards.
5. The Eastern Cooperative Oncology Group (ECOG) scoring system in the United States has a score range of 0-2.
6. Total bilirubin ≤1.5× upper limit of normal (ULN); AST and AST \<2.5× upper limit of normal (ULN).(No liver metastasis), or \<5 times the upper limit of normal (ULN) (with liver metastasis);
7. Patients with recurrent metastasis who have not previously received immunotherapy such as PD-1, PD-L1, CTLA-4 antibodies，also allowed for the enrollment of patients who had used adjuvant/neoadjuvant therapies

   * If the adjuvant or neoadjuvant treatment plan includes PD(L)-1 or CTLA-4 monoclonal antibodies, it is required that only those who progress more than 6 months after the end of the treatment plan can be included in the study group.
   * If the adjuvant or neo-adjuvant treatment plan does not include PD(L)-1 or CTLA-4 monoclonal antibodies, patients who progress during the adjuvant treatment are allowed to participate in the study.
8. Has signed the informed consent form, able to comply with the study protocol and follow-up plan.

Exclusion Criteria:

1. Received treatment involving PD-1, PD-L1, or CTLA-4 antibody regimen within the past 6 months;
2. Patients who have received treatment with thymosin, thymopentin, or thymosin a-1d within 3 months prior to enrollment.
3. Presence of symptomatic central nervous system (CNS) metastases and/or carcinomatous meningitis. For subjects with previously treated CNS metastases, if the subject's condition is stable (no evidence of radiographic progression for at least weeks prior to the first administration of the study intervention, and all neurological symptoms have returned to baseline), repeat radiographic examination confirms no evidence of new brain metastases or enlargement of existing brain metastases, and no need for steroid treatment for at least 14 days prior to the first administration of the study intervention, they may participate in the study.
4. Patients with active systemic autoimmune diseases requiring systemic treatment (i.e., using immunomodulators, corticosteroids, or immunosuppressants). Replacement therapies (such as thyroxine, insulin, or physiological corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) are not considered systemic treatment.
5. Has a history of immunodeficiency, including testing positive for HIV, or suffering from other acquired or congenital immunodeficiency diseases, or has a history of organ transplantation and bone marrow transplantation.

6）Allergic to the investigational drug or its components; 7）Presence of active infection requiring systemic treatment; 8) Uncontrolled internal medical complications, such as unstable congestive heart failure, unstable angina, myocardial infarction, cerebrovascular accidents, and hemodynamically unstable arrhythmias, etc.

9\) The investigator deems them unsuitable for inclusion.

Where it's running

• Sun yat-sen uniersity
  Guangzhou, Guangdong, China Recruiting
• Nanshan hospital
  Shenzhen, Guangdong, China Recruiting

Study contacts

• Principal investigator: Penghui Zhou, PhD
• Study coordinator: Xizhi Wen, PhD
• Email: wenxzh@sysucc.org.cn
• Phone: +8602087343381

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Assessment of cardiovascular issues in cancer patients on immune checkpoint inhibitors

  This study is trying to see if cancer patients treated with immune checkpoint inhibitors have heart problems and how those issues affect their health.

  Recruiting Institut Mutualiste Montsouris · Paris · NCT05799898

• Melanoma treatment with immunotherapy guided by serial ctDNA testing

  This trial tests whether regular ctDNA blood tests during treatment can help tailor the plan for patients with advanced melanoma receiving nivolumab and ipilimumab.

  Recruiting Phase 2 H. Lee Moffitt Cancer Center and Research Institute · Tampa, Florida · NCT07930182

• Non-invasive skin-tape test to detect melanoma using methylation biomarkers

  A non-invasive skin-tape test is being tried to see if it can detect melanoma in people who are about to have a biopsy for a suspicious pigmented lesion.

  Recruiting at 4 sites Mitra Bio · Ghent and 4 other locations · NCT07883954

• SI-B036 safety test in advanced and metastatic solid tumors

  This early-phase study checks whether SI-B036 is safe and tolerable in adults with advanced or metastatic solid cancers who have had prior therapy.

  Recruiting at 4 sites Phase 1 SystImmune Inc. · New Haven, Connecticut and 6 other locations · NCT07857616

• BL-M08D treatment in melanoma and other solid tumors

  A phase Ib/II study tests BL-M08D1 injections in adults with locally advanced or metastatic melanoma and other solid tumors to see if it is safe and helpful.

  Recruiting Phase 1/2 Sichuan Baili Pharmaceutical Co., Ltd. · Beijing, Beijing Municipality · NCT07841925

• Granzyme B-PET to see if immunotherapy works in TNBC

  This study will test whether a Granzyme B PET/CT scan can help predict how well immunotherapy will work for adults with locally advanced or metastatic triple-negative breast cancer receiving an immune checkpoint inhibitor.

  Recruiting Fudan University · Shanghai · NCT07705438

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.